BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR446523 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR446523\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06630806-3383@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20310516
DTEND;VALUE=DATE:20310517
SUMMARY:SAR446523: Phase 1 readout est. (NCT06630806)
DESCRIPTION:SAR446523\, phase 1\, Multiple Myeloma.\nStudy: A Study to Inve
 stigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Ad
 ult Participants With Relapsed/Refractory Myeloma\nEstimated primary compl
 etion: 16 May 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 ar446523#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06630806
URL:https://assetmemo.bio/drug/sar446523#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
